Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1970 3
1971 4
1972 1
1973 2
1974 2
1976 1
1977 4
1978 5
1979 1
1980 2
1981 2
1982 1
1983 7
1984 4
1985 3
1986 5
1987 5
1988 6
1989 2
1990 8
1991 8
1992 7
1993 16
1994 12
1995 12
1996 14
1997 19
1998 15
1999 27
2000 36
2001 28
2002 46
2003 39
2004 62
2005 71
2006 89
2007 101
2008 108
2009 137
2010 153
2011 233
2012 239
2013 221
2014 244
2015 320
2016 257
2017 262
2018 282
2019 251
2020 265
2021 278
2022 237
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,699 results
Results by year
Filters applied: . Clear all
Page 1
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. Kang YK, et al. Among authors: park ys. J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16. J Clin Oncol. 2021. PMID: 34133211 Free PMC article. Clinical Trial.
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.
Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. Park SH, et al. Among authors: park ys. Ann Oncol. 2021 Mar;32(3):368-374. doi: 10.1016/j.annonc.2020.11.017. Epub 2020 Dec 3. Ann Oncol. 2021. PMID: 33278599 Free article. Clinical Trial.
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. Hirsch C, et al. Among authors: park ys. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. Cochrane Database Syst Rev. 2022. PMID: 35713300 Review.
Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease.
Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, Leng L, Jo S, Park YS, Kusuda M, Machhar R, Boroojeni SF, Wu B, Rossomacha E, Kim TH, Ciccia F, Rockel JS, Kapoor M, Inman RD, Jurisica I, Crome SQ, Bucala R, Haroon N. Nakamura A, et al. Among authors: park ys. Sci Transl Med. 2021 Oct 20;13(616):eabg1210. doi: 10.1126/scitranslmed.abg1210. Epub 2021 Oct 20. Sci Transl Med. 2021. PMID: 34669443
T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling.
Marchelletta RR, Krishnan M, Spalinger MR, Placone TW, Alvarez R, Sayoc-Becerra A, Canale V, Shawki A, Park YS, Bernts LH, Myers S, Tremblay ML, Barrett KE, Krystofiak E, Kachar B, McGovern DP, Weber CR, Hanson EM, Eckmann L, McCole DF. Marchelletta RR, et al. Among authors: park ys. J Clin Invest. 2021 Sep 1;131(17):e138230. doi: 10.1172/JCI138230. J Clin Invest. 2021. PMID: 34623320 Free PMC article.
3,699 results